Comparative Pharmacology
Head-to-head clinical analysis: PRIMAQUINE versus SOVUNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRIMAQUINE versus SOVUNA.
PRIMAQUINE vs SOVUNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antimalarial agent that eliminates exoerythrocytic forms (hypnozoites) of Plasmodium vivax and P. ovale; also active against gametocytes. Mechanism involves generation of reactive oxygen species via redox cycling, disrupting parasite mitochondrial function.
SOVUNA (suvorexant) is a dual orexin receptor antagonist that blocks the binding of orexin neuropeptides to orexin OX1 and OX2 receptors, thereby promoting sleep initiation and maintenance.
15 mg (base) orally once daily for 14 days for radical cure of P. vivax and P. ovale; 30 mg (base) orally once daily for 7 days for terminal prophylaxis.
400 mg orally once daily with food.
None Documented
None Documented
Clinical Note
moderatePrimaquine + Norfloxacin
"Primaquine may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderatePrimaquine + Haloperidol
"Primaquine may increase the QTc-prolonging activities of Haloperidol."
Clinical Note
moderatePrimaquine + Ibandronate
"Primaquine may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderatePrimaquine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Primaquine."
Terminal elimination half-life of approximately 4-7 hours; in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, half-life may be prolonged due to accumulation in erythrocytes
Terminal half-life 14 hours; clinically significant for once-daily dosing, requiring dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (60-65% as unchanged drug and metabolites); small amounts in feces (<5%)
Primarily renal (70% unchanged) and 20% fecal via bile; minor metabolic clearance.
Category D/X
Category C
Antimalarial
Antimalarial